Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Age-related Macular Degeneration (AMD): full-pipeline trial registry
4 of 8 indexed Age-related Macular Degeneration (AMD) trials are currently recruiting.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Age-related Macular Degeneration (AMD): 8 US clinical trials tracked, 4 recruiting.
Age-related Macular Degeneration (AMD) is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition age-related-macular-degeneration-amd
OPEN 4 | RECR 50% | LATE 1 | EARLY 1 | RANK #2176 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Age-related Macular Degeneration (AMD) lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Age-related Macular Degeneration (AMD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Age-related Macular Degeneration (AMD) is recruiting above its size-band peers.
4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Age-related Macular Degeneration (AMD) research.
Novartis Pharmaceuticals accounts for 3 of 8 trials (37.5%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Age-related Macular Degeneration (AMD) enrolment sits around 1,076 participants.
Median target enrolment is 1,076 among the 8 trials that report a genuine target (sentinel values excluded). 1 of those (12.5%) plan for fewer than 100 participants.
-
Age-related Macular Degeneration (AMD) research leans observational.
3 interventional and 5 observational studies make up this index (37.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
iHealthScreen
NCT07084883
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals
NCT06541704
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
NCT06659445
Active AMD Study to Improve Function in Veterans
VA Office of Research and Development
NCT05932069
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
Novartis Pharmaceuticals
NCT05146687
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Novartis Pharmaceuticals
NCT05110209
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
Novartis Pharmaceuticals
NCT05111743
Genetics and Markers of Degenerative and Inflammatory Eye Diseases
National Eye Institute (NEI)
NCT00647439
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Age-related Macular Degeneration (AMD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Age-related Macular Degeneration (AMD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Age-related Macular Degeneration (AMD) page
8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Age-related Macular Degeneration (AMD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Age-related Macular Degeneration (AMD) trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Age-related Macular Degeneration (AMD) condition card totals 8 registered trials; most-linked intervention Bevacizumab; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.